Lupin Pharmaceuticals Inc. has voluntarily recalled 6,540 bottles of Metformin Hydrochloride Extended-release Tablets USP (500 mg, 60-count bottles) after FDA testing revealed the presence of an impurity called N-Nitrosodimethylamine (NDMA). NDMA is classified as a probable human carcinogen, meaning long-term exposure to levels above acceptable limits may increase the risk of cancer. This recall affects generic Metformin (an Rx medication) with NDC number 68180-336-07 and expiration date 12/2020. Consumers should continue taking their medication but contact their doctor or pharmacist immediately for a replacement or alternative treatment to avoid health risks from stopping their diabetes medication abruptly.
The tablets contain N-Nitrosodimethylamine (NDMA) at levels that exceed the acceptable daily intake limit. NDMA is a known environmental contaminant and is classified as a probable human carcinogen based on results from laboratory tests.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES ยท Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.